Meeting
2014 ASCO Annual Meeting
Combined epiregulin (EREG) and amphiregulin (AREG) expression levels as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC).
Authors
Jenny F. Seligmann
University of Leeds, Leeds, United Kingdom
Jenny F. Seligmann , Faye Elliott , Susan Richman , Bart Jacobs , Gemma Hemmings , Jenny Barrett , Sabine Tejpar , Philip Quirke , Matthew T. Seymour
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 3520)
DOI
10.1200/jco.2014.32.15_suppl.3520
Abstract #
3520
Poster Bd #
8
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
HER3 as a biomarker of prognosis and panitumumab (Pan) benefit in RAS-wt advanced colorectal cancer (aCRC).
First Author: Jenny F. Seligmann
Poster
2015 ASCO Annual Meeting
Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab benefit in RAS-wt advanced colorectal cancer (aCRC): Analysis of patients (pts) from the PICCOLO trial.
First Author: Pierre Laurent-Puig
Poster
2012 Markers in Cancer
Use of epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab (cet) in combination with oxaliplatin (Ox) and 5FU in the first-line treatment of advanced colorectal cancer (aCRC).
First Author: Richard Adams
Poster
2024 ASCO Gastrointestinal Cancers Symposium
High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness.
First Author: Ramya Thota